Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Glenmark Pharmaceuticals Yönetim
Yönetim kriter kontrolleri 1/4
Glenmark Pharmaceuticals' CEO'su Glenn Saldanha, Jan2001 tarihinde atandı, in görev süresi 23.75 yıldır. in toplam yıllık tazminatı ₹ 168.61M olup, şirket hissesi ve opsiyonları dahil olmak üzere 80% maaş ve 20% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.35% ine doğrudan sahiptir ve bu hisseler ₹ 1.65B değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.5 yıl ve 6.4 yıldır.
Anahtar bilgiler
Glenn Saldanha
İcra Kurulu Başkanı
₹168.6m
Toplam tazminat
| CEO maaş yüzdesi | 80.0% |
| CEO görev süresi | 23.8yrs |
| CEO sahipliği | 0.4% |
| Yönetim ortalama görev süresi | 1.5yrs |
| Yönetim Kurulu ortalama görev süresi | 6.4yrs |
Son yönetim güncellemeleri
This Is Why Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation Looks Appropriate
Sep 21
Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 23Recent updates
This Is Why Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation Looks Appropriate
Sep 21Glenmark Pharmaceuticals (NSE:GLENMARK) Is Paying Out A Dividend Of ₹2.50
Sep 06Calculating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Aug 06Does Glenmark Pharmaceuticals (NSE:GLENMARK) Have A Healthy Balance Sheet?
Jun 16Is Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Expensive For A Reason? A Look At Its Intrinsic Value
May 08Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt
Mar 09Is Glenmark Pharmaceuticals (NSE:GLENMARK) Using Too Much Debt?
Dec 07Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 23Glenmark Pharmaceuticals (NSE:GLENMARK) Will Pay A Dividend Of ₹2.50
Sep 17Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50
Aug 30A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Aug 28We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Is Taking Some Risk With Its Debt
Jul 03A Look At The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
May 28Glenmark Pharmaceuticals (NSE:GLENMARK) Has A Somewhat Strained Balance Sheet
Mar 22Estimating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Feb 14An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 37% Undervalued
Oct 12Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 21Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50
Aug 29We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt
Jun 20There May Be Reason For Hope In Glenmark Pharmaceuticals' (NSE:GLENMARK) Disappointing Earnings
Jun 04An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 27% Undervalued
May 05If You Like EPS Growth Then Check Out Glenmark Pharmaceuticals (NSE:GLENMARK) Before It's Too Late
Mar 25CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -₹16b |
| Mar 31 2024 | ₹169m | ₹135m | -₹19b |
| Dec 31 2023 | n/a | n/a | -₹8b |
| Sep 30 2023 | n/a | n/a | -₹1b |
| Jun 30 2023 | n/a | n/a | ₹3b |
| Mar 31 2023 | ₹162m | ₹130m | -₹2b |
| Dec 31 2022 | n/a | n/a | ₹9b |
| Sep 30 2022 | n/a | n/a | ₹8b |
| Jun 30 2022 | n/a | n/a | ₹8b |
| Mar 31 2022 | ₹158m | ₹130m | ₹9b |
| Dec 31 2021 | n/a | n/a | ₹10b |
| Sep 30 2021 | n/a | n/a | ₹10b |
| Jun 30 2021 | n/a | n/a | ₹10b |
| Mar 31 2021 | ₹139m | ₹110m | ₹10b |
| Dec 31 2020 | n/a | n/a | ₹10b |
| Sep 30 2020 | n/a | n/a | ₹9b |
| Jun 30 2020 | n/a | n/a | ₹9b |
| Mar 31 2020 | ₹122m | ₹91m | ₹8b |
| Dec 31 2019 | n/a | n/a | ₹7b |
| Sep 30 2019 | n/a | n/a | ₹6b |
| Jun 30 2019 | n/a | n/a | ₹8b |
| Mar 31 2019 | ₹157m | ₹131m | ₹9b |
| Dec 31 2018 | n/a | n/a | ₹9b |
| Sep 30 2018 | n/a | n/a | ₹9b |
| Jun 30 2018 | n/a | n/a | ₹7b |
| Mar 31 2018 | ₹162m | ₹134m | ₹8b |
Tazminat ve Piyasa: Glenn 'nin toplam tazminatı ($USD 2.01M ), Indian pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 637.49K ).
Tazminat ve Kazançlar: Glenn şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.
CEO
Glenn Saldanha (54 yo)
23.8yrs
Görev süresi
₹168,610,000
Tazminat
Mr. Glenn Mario Saldanha has been the Managing Director and Chief Executive Officer of Glenmark Pharmaceuticals Limited since 2000. Mr. Saldanha serves as Chairman at Ichnos Sciences Inc. Mr. Saldanha serv...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Chairman | 23.8yrs | ₹168.61m | 0.35% ₹ 1.7b | |
| Executive Director of Corporate Services & Executive Director | no data | ₹60.84m | 0.27% ₹ 1.3b | |
| Executive Director | less than a year | ₹102.12m | Veri yok | |
| Company Secretary & Compliance Officer | 7.7yrs | ₹5.53m | Veri yok | |
| President and Chief Human Resources Officer | 2.8yrs | Veri yok | Veri yok | |
| President & Head of Global Pharmaceutical Development | 2.1yrs | Veri yok | Veri yok | |
| President & Chief Quality Officer | 1.1yrs | Veri yok | Veri yok | |
| President & Global Head of Formulation Operations | 1.1yrs | Veri yok | Veri yok | |
| President & Business Head of India Formulations | 1.2yrs | Veri yok | Veri yok | |
| President and Business Head of Europe & Emerging Markets | 1.8yrs | Veri yok | Veri yok | |
| President & Business Head of North America | less than a year | Veri yok | Veri yok | |
| Investor Relations Officer | no data | Veri yok | Veri yok |
1.5yrs
Ortalama Görev Süresi
55yo
Ortalama Yaş
Deneyimli Yönetim: GLENMARK 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.5 yıl), bu da yeni bir ekibin varlığını gösteriyor.
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Chairman | 26yrs | ₹168.61m | 0.35% ₹ 1.7b | |
| Executive Director of Corporate Services & Executive Director | 25yrs | ₹60.84m | 0.27% ₹ 1.3b | |
| Executive Director | 6.4yrs | ₹102.12m | Veri yok | |
| President | less than a year | Veri yok | Veri yok | |
| Non Executive Director | 19.2yrs | ₹600.00k | 0.39% ₹ 1.9b | |
| Non-Executive Independent Director | 22.4yrs | ₹1.90m | 0.039% ₹ 189.8m | |
| Independent Non-Executive Director | 1.7yrs | ₹1.20m | Veri yok | |
| Independent Non-Executive Director | 4.2yrs | ₹1.10m | Veri yok | |
| Independent Non-Executive Director | 5.5yrs | ₹1.40m | Veri yok |
6.4yrs
Ortalama Görev Süresi
61yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: GLENMARK 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.4 yıldır).